현재 위치
Home
Medical / Pharmaceutical Biotechnology Symposium : 좌장 : 조의철 박사(목암생명공학연구소)
Analysis of Efficacy and Safety of Novel Sustained Release rhGH (LB03002) Given Once-a-week to Adults in GHD
-
- 발행기관
- 한국생물공학회 바로가기
-
- 간행물
- 한국생물공학회 학술대회 바로가기
-
- 통권
- 2009 추계학술대회 및 국제심포지움 (2009.11)바로가기
-
- 페이지
- pp.91-91
-
- 저자
-
- 언어
- 영어(ENG)
-
- URL
- https://www.earticle.net/Article/A114453
※ 원문제공기관과의 협약기간이 종료되어 열람이 제한될 수 있습니다.
원문정보
초록
- 영어
- The protein therapeutics are mostly parenteral formulations due to the characteristics of protein with a low stability or fragility. It results the frequent injection of medication to treat the patients for long period. To satisfy the unmet medical need of patients such as reducing the number of injection or changing the route of administration, the new formulations of products are developed such as a long-acting form of product utilizing DDS(Drug Delivery System) technique. The recent achievement of DDS techniques derives the products available to satisfy the unmet medical needs of less frequent injection, emerging as a new technologyf protein therapeutics development by adding a higher value on the patent-off biopharmaceuticals. There are few cases of microparticle formulations used as long-acting or slow releasing protein or peptide therapeutics developed using biodegradable and biocompatible polymers as matrix material. Depending on the action mechanisms of targeted therapeutic proteins, the products are to be designed by control of biodegradation rate with selection of polymers in terms of molecular weight, the ratio of mixing ingredients, and hydrophilic property. The achievable technique of long-acting or slow releasing microparticle formulation for development of protein or peptide therapeutics is limited so far. The desire and expectation for a better hGH(human growth hormone) product has driven a number of pharmaceutical companies to develop SR-hGH (sustained-release hGH) products. LB03002 is the biocompatible hyaluronic acid-based formulation with promising features such as, complete release of hGH, structural integrity/activity of hGH, easy administration with 26 gauge needle, and no significant injection site reaction. Moreover, the clinical data obtained at present demonstrate the bioavailability, efficacy and safety of LB03002 comparable to those of daily injection products. The efficacy and safety of LB03002 administered once-aweek in adults with GHD(growth hormone deficiency) were evaluated in a phase III clinical study, completed recently. The clinical study results will be presented to discuss how well be designed based on its action mechanism.
저자
간행물 정보
발행기관
-
- 발행기관명
- 한국생물공학회 [The Korean Society for Biotechnology and Bioengineering]
- 설립연도
- 1984
- 분야
- 공학>생물공학
- 소개
- 이 법인은 생물 공학의 발전과 보급에 이바지하고, 회원 상호 간의 연구 협력과 친목을 도모함을 목적으로 한다 1. 생물공학 분야의 발전을 위한 연구 협력 2. 생물공학의 실용화를 촉진시키기 위한 산학 협동 3. 학술연구 발표회, 강연회, 연수회 등 학술활동의 개최 4. 국,영문 학술지,소식지,학술회의 Proceedings 및 학술도서의 발간 5. 생물공학 발전을 위한 정책 건의 6. 기타 국제 교류 등 본 학회의 목적 달성을 위한 제반 활동
간행물
-
- 간행물명
- 한국생물공학회 학술대회
- 간기
- 반년간
- 수록기간
- 1985~2013
- 십진분류
- KDC 476 DDC 576
이 권호 내 다른 논문 / 한국생물공학회 학술대회 2009 추계학술대회 및 국제심포지움
피인용수 : 0건 (자료제공 : 네이버학술정보)
함께 이용한 논문 이 논문을 다운로드한 분들이 이용한 다른 논문입니다.
출처 : 네이버학술정보
0개의 논문이 장바구니에 담겼습니다.